U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C21H27NO.ClH
Molecular Weight 345.906
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METHADONE HYDROCHLORIDE

SMILES

Cl.CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2

InChI

InChIKey=FJQXCDYVZAHXNS-UHFFFAOYSA-N
InChI=1S/C21H27NO.ClH/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19;/h6-15,17H,5,16H2,1-4H3;1H

HIDE SMILES / InChI
Molecular Formula C21H27NO
Molecular Weight 309.4452
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/006134s040s041lbl.pdf | https://www.drugs.com/pro/diskets.html

Methadone, sold under the brand names Dolophine among others, is an synthetic opioid that is used as the hydrochloride to treat pain and as maintenance therapy or to help with detoxification in people with opioid dependence. Methadone hydrochloride is a mu-agonist; a synthetic opioid analgesic with multiple actions qualitatively similar to those of morphine. Some data also indicate that methadone acts as an antagonist at the NMDA-receptor. The contribution of NMDA receptor antagonism to methadone’s efficacy is unknown. Most common adverse reactions are: lightheadedness, dizziness, sedation, nausea, vomiting, and sweating. Avoid use mixed agonist/antagonist and partial agonist opioid analgesics with DOLOPHINE because they may reduce analgesic effect of DOLOPHINE or precipitate withdrawal symptoms.

CNS Activity

CNS Active
4002
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/5084666

Originator

Approval Year

1947
100
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 3.51 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8583
DOLOPHINE HYDROCHLORIDE

Approved Use

For the treatment of moderate to severe pain not responsive to non-narcotic analgesics. For detoxification treatment of opioid addiction (heroin or other morphine-like drugs). For maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. Note – Outpatient maintenance and outpatient detoxification treatment may be provided only by Opioid Treatment Programs (OTPs) certified by the Federal Substance Abuse and Mental Health Services Administration (SAMHSA) and registered by the Drug Enforcement Administration (DEA). This does not preclude the maintenance treatment of a patient with concurrent opioid addiction who is hospitalized for conditions other than opioid addiction and who requires temporary maintenance during the critical period of his/her stay, or of a patient whose enrollment has been verified in a program which has been certified for maintenance treatment with methadone.

Launch Date

1947
Palliative
Approved
8583
DOLOPHINE HYDROCHLORIDE

Approved Use

For the treatment of moderate to severe pain not responsive to non-narcotic analgesics. For detoxification treatment of opioid addiction (heroin or other morphine-like drugs). For maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. Note – Outpatient maintenance and outpatient detoxification treatment may be provided only by Opioid Treatment Programs (OTPs) certified by the Federal Substance Abuse and Mental Health Services Administration (SAMHSA) and registered by the Drug Enforcement Administration (DEA). This does not preclude the maintenance treatment of a patient with concurrent opioid addiction who is hospitalized for conditions other than opioid addiction and who requires temporary maintenance during the critical period of his/her stay, or of a patient whose enrollment has been verified in a program which has been certified for maintenance treatment with methadone.

Launch Date

1947
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
494 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/15151520/
76 mg 1 times / day steady-state, oral
dose: 76 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
METHADONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
40.2 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/22621465/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHADONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
548 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8641323/
0.89 mg/kg 1 times / day steady-state, oral
dose: 0.89 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
METHADONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
54 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8641323/
0.89 mg/kg 1 times / day steady-state, oral
dose: 0.89 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
8.27 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/15151520/
76 mg 1 times / day steady-state, oral
dose: 76 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
METHADONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1073 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/22621465/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHADONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
8.54 mg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8641323/
0.89 mg/kg 1 times / day steady-state, oral
dose: 0.89 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
METHADONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
0.61 mg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8641323/
0.89 mg/kg 1 times / day steady-state, oral
dose: 0.89 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
39 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/15151520/
76 mg 1 times / day steady-state, oral
dose: 76 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
METHADONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
39.3 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/22621465/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHADONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
31.2 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8641323/
0.89 mg/kg 1 times / day steady-state, oral
dose: 0.89 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
METHADONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
10 mg 3 times / day multiple, intravenous
Recommended
Dose: 10 mg, 3 times / day
Route: intravenous
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf
Other AEs: Withdrawal syndrome neonatal...
Other AEs:
Withdrawal syndrome neonatal
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf
10 mg 3 times / day multiple, intravenous
Recommended
Dose: 10 mg, 3 times / day
Route: intravenous
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf
Other AEs: Respiratory depression, Addiction...
Other AEs:
Respiratory depression (grade 5)
Addiction
QT interval prolonged (grade 5)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf
20 mg single, oral
Recommended
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017058s026lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017058s026lbl.pdf
Other AEs: Respiratory depression, QT interval prolonged...
Other AEs:
Respiratory depression (grade 5)
QT interval prolonged
Arrhythmia (serious)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017058s026lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Withdrawal syndrome neonatal
10 mg 3 times / day multiple, intravenous
Recommended
Dose: 10 mg, 3 times / day
Route: intravenous
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf
Addiction
10 mg 3 times / day multiple, intravenous
Recommended
Dose: 10 mg, 3 times / day
Route: intravenous
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf
QT interval prolonged grade 5
10 mg 3 times / day multiple, intravenous
Recommended
Dose: 10 mg, 3 times / day
Route: intravenous
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf
Respiratory depression grade 5
10 mg 3 times / day multiple, intravenous
Recommended
Dose: 10 mg, 3 times / day
Route: intravenous
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf
QT interval prolonged
20 mg single, oral
Recommended
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017058s026lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017058s026lbl.pdf
Respiratory depression grade 5
20 mg single, oral
Recommended
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017058s026lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017058s026lbl.pdf
Arrhythmia serious
20 mg single, oral
Recommended
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017058s026lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017058s026lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946

inhibitor
2252
substrate
1193
substrate
1388

inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2E1
1060

CYP1A
70

CYP2B
16

CYP2C
20

UGT2B7
197

UGT2B4
23
CYP2B6
776

CYP2C19
1119

P-gp
2052

OATP1A2
67

OATP1B1
503

OATP1B3
435

OATP2B1
122

OCT1
393

OCT2
434

OCT3
92

BCRP
697
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
UGT2B4
23
 major [Inhibition 0.6 uM]
CYP1A
122
 no
CYP2B
41
 no
CYP2C
37
 no
CYP2E1
1146
 no
UGT2B7
210
 unlikely
CYP3A4
2633
 yes [Ki 100 uM]
CYP2D6
2546
 yes [Ki 2.5 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
BCRP
697
 no
OATP1A2
67
 no
OATP1B1
503
 no
OATP1B3
435
 no
OATP2B1
122
 no
OCT1
393
 no
OCT2
434
 no
OCT3
92
 no
P-gp
2052
 yes
CYP2B6
776
 yes
yes (co-administration study)
Comment: CYP450 inducers: concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms; phenytoin administration resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. CYP450 inhibitors: Repeat dose administration of oral voriconazole increased the peak plasma concentration (Cmax) and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose. The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively
Page: 29.0
CYP2C19
1119
 yes
yes (co-administration study)
Comment: CYP450 inducers: concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms; phenytoin administration resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. CYP450 inhibitors: Repeat dose administration of oral voriconazole increased the peak plasma concentration (Cmax) and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose. The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively
Page: 29.0
CYP2C9
1193
 yes
yes (co-administration study)
Comment: CYP450 inducers: concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms; phenytoin administration resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. CYP450 inhibitors: Repeat dose administration of oral voriconazole increased the peak plasma concentration (Cmax) and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose. The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively
Page: 29.0
CYP2D6
1388
 yes
yes (co-administration study)
Comment: CYP450 inducers: concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms; phenytoin administration resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. CYP450 inhibitors: Repeat dose administration of oral voriconazole increased the peak plasma concentration (Cmax) and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose. The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively
Page: 29.0
CYP3A4
1946
 yes
yes (co-administration study)
Comment: CYP450 inducers: concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms; phenytoin administration resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. CYP450 inhibitors: Repeat dose administration of oral voriconazole increased the peak plasma concentration (Cmax) and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose. The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively
Page: 29.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:6807
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6807
eMolecules
979329
https://www.emolecules.com/cgi-bin/more?vid=979329
PubMed

PubMed

TitleDatePubMed
Rhabdomyolysis and acute renal failure following methadone abuse.
1992
Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance.
2000 Apr
Methadone, ciprofloxacin, and adverse drug reactions.
2000 Dec 16
Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts.
2000 Feb
Thrice-weekly versus daily buprenorphine maintenance.
2000 Jun 15
[Methadone withdrawal syndrome induced by nevirapine].
2000 Mar 18
Methadone maintenance treatment (MMT): a review of historical and clinical issues.
2000 Oct-Nov
Intravenous clonidine use in a neonate experiencing opioid-induced myoclonus.
2001 Aug
Effect of perinatal buprenorphine exposure on development in the rat.
2001 Aug
Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine.
2001 Aug
Reversible spastic paraparesis induced by high-dose intravenous methadone.
2001 Feb
Family history influence on drug abuse severity and treatment outcome.
2001 Feb 1
Methadone-induced myoclonus in advanced cancer.
2001 Jan-Feb
Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent.
2001 Jul 1
Reversible delirium during opiod switching from transdermal fentanyl to methadone.
2001 Mar
Sleep-disordered breathing in stable methadone programme patients: a pilot study.
2001 Mar
Efficacy of an enteral 10-day methadone wean to prevent opioid withdrawal in fentanyl-tolerant pediatric intensive care unit patients.
2001 Oct
Neuropsychological correlates of opioid dependence and withdrawal.
2003 Apr
Bile duct dilation with chronic methadone use in asymptomatic patients: ERCP findings in 6 patients.
2003 Jul
Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes.
2003 Jun
Methadone treatment induces attenuation of cerebrovascular deficits associated with the prolonged abuse of cocaine and heroin.
2003 Mar
Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study.
2003 Nov
QTc interval prolongation associated with intravenous methadone.
2003 Oct
Safety of injectable opioid maintenance treatment for heroin dependence.
2003 Oct 15
Relationship between prescribing and risk of opiate overdose among drug users in and out of maintenance treatment.
2004
Cost effectiveness of disulfiram: treating cocaine use in methadone-maintained patients.
2004 Apr
Directly observed therapy for the management of HIV-infected patients in a methadone program.
2004 Jun 1
The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.
2004 May
Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials.
2004 May
Intravenous ketamine infusion as an adjuvant to morphine in a 2-year-old with severe cancer pain from metastatic neuroblastoma.
2004 Oct
Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes.
2005 Apr
Dextromethorphan-induced delirium and possible methadone interaction.
2005 Mar
Methadone-induced Torsade de pointes tachycardias.
2005 May 14
Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence.
2006 Jan
Bradycardia during methadone therapy in an infant.
2006 Jan
A randomized controlled trial of interim methadone maintenance.
2006 Jan
Changes in HIV risk behaviors among patients receiving combined pharmacological and behavioral interventions for heroin and cocaine dependence.
2006 May
Patents

Patents

JP2000212069A
13
JP2002527384A
13
JP2007507532A
35
JP2007525670A
150
JP2011528275A
456
JPH02247157A
4

Sample Use Guides

In Vivo Use Guide
Chronic pain: oral initial dose - 2.5 mg every 8 to 12 hours; Intravenous initial dose: 2.5 mg to 10 mg every 8 to 12 hours Opiate withdrawal: Initial dose - 20 to 30 mg orally; an additional 5 to 10 mg may be given orally after 2 to 4 hours if withdrawal symptoms have not been suppressed or if symptoms reappear. -Maximum initial dose: 30 mg -Maximum day 1 dose: 40 mg
Route of Administration: Other
In Vitro Use Guide
In the presence of 1 uM methadone, the maximum 86Rb+ efflux stimulated by nicotine (Emax) was markedly reduced, but the EC50 for nicotine was altered only slightly, if at all.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:50:41 GMT 2025
Edited
by admin
on Mon Mar 31 17:50:41 GMT 2025
Record UNII
229809935B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METHADONE HYDROCHLORIDE CII
USP-RS  
Preferred Name English
METHADONE HYDROCHLORIDE
EP   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
Common Name English
METHADONE HYDROCHLORIDE CII [USP-RS]
Common Name English
METHADONE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
METHADONE HYDROCHLORIDE [JAN]
Common Name English
4,4-DIPHENYL-6-DIMETHYLAMINO-3-HEPTANONE HYDROCHLORIDE
Systematic Name English
6-(Dimethylamino)-4,4-diphenyl-3-heptanone hydrochloride
Systematic Name English
Methadone hydrochloride [WHO-DD]
Common Name English
METHADONE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
3-HEPTANONE, 6-(DIMETHYLAMINO)-4,4-DIPHENYL-, HYDROCHLORIDE
Systematic Name English
DL-6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANONE HYDROCHLORIDE
Common Name English
FENADONE
Brand Name English
METHADONE HYDROCHLORIDE [MI]
Common Name English
BUTALGIN
Brand Name English
METHADOSE
Brand Name English
AN-148
Code English
METHADONE HYDROCHLORIDE [USP-RS]
Common Name English
DOLOPHINE HYDROCHLORIDE
Brand Name English
MECODIN
Brand Name English
PHENADONE HYDROCHLORIDE
Common Name English
NSC-19600
Code English
HEPTADON
Brand Name English
METHADONE HCL
Common Name English
METHADONE HYDROCHLORIDE [EP IMPURITY]
Common Name English
METHADONE HYDROCHLORIDE [VANDF]
Common Name English
METHADONE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
WESTADONE
Brand Name English
3-HEPTANONE, 6-(DIMETHYLAMINO)-4,4-DIPHENYL-, HYDROCHLORIDE (1:1)
Systematic Name English
KETALGIN HYDROCHLORIDE
Brand Name English
ADANON HYDROCHLORIDE
Brand Name English
DOLOPHINE
Brand Name English
DOLOFIN HYDROCHLORIDE
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C1506
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
DEA NO. 9250
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
NCI_THESAURUS C67413
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
Code System Code Type Description
ChEMBL
CHEMBL651
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
PUBCHEM
14184
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
RXCUI
218337
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY RxNorm
CAS
70181-39-4
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
SUPERSEDED
DRUG BANK
DBSALT000346
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
CAS
70172-45-1
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
SUPERSEDED
EPA CompTox
DTXSID2020501
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
SMS_ID
100000091446
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
CAS
1095-90-5
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
ECHA (EC/EINECS)
214-140-7
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
DAILYMED
229809935B
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
NSC
19600
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
FDA UNII
229809935B
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
EVMPD
SUB03203MIG
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
CHEBI
50140
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
RS_ITEM_NUM
1398009
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
CAS
125-56-4
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
SUPERSEDED
MERCK INDEX
m7286
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY Merck Index
NCI_THESAURUS
C638
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
Related Record Type Details
Structure of METHADONE
PARENT -> SALT/SOLVATE
Structure of ESMETHADONE HYDROCHLORIDE
ENANTIOMER -> RACEMATE
Structure of LEVOMETHADONE HYDROCHLORIDE
ENANTIOMER -> RACEMATE
Structure of METHADONE HYDROCHLORIDE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Structure of METHADONE HYDROCHLORIDE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
Related Record Type Details
Structure of 2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE
METABOLITE INACTIVE -> PARENT
Cytochrome P450 enzymes, primarily CYP3A4, CYP2B6, and CYP2C19 and to a lesser extent CYP2C9 and CYP2D6, are responsible for conversion of methadone to EDDP and other inactive metabolites, which are excreted mainly in the urine.
Related Record Type Details
Structure of ISOMETHADONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
EP
Structure of N-nitroso-desmethyl-methadone
IMPURITY -> PARENT
Structure of ISOMETHADONE KETIMINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
EP
Structure of ISODIDIAVALO
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
EP
Structure of DIPHENYLACETONITRILE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
EP
Structure of DIDIAVALO
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
EP
Related Record Type Details
Structure of METHADONE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966